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Aim To investigate theputative modifyingeffectofdual antiplatelet therapy (DAPT) useonthe incidenceof stent thrombosis at 3
years in patients randomized to Endeavor zotarolimus-eluting stent (E-ZES) or Cypher sirolimus-eluting stent (C-SES).
Methods
and results
Of 8709 patients in PROTECT, 4357 were randomized to E-ZES and 4352 to C-SES. Aspirin was to be given indefinitely,
and clopidogrel/ticlopidine for≥3 months or up to 12 months after implantation. Main outcome measures were definite
or probable stent thrombosis at 3 years. Multivariable Cox regression analysis was applied, with stent type, DAPT, and
their interaction as the main outcome determinants. Dual antiplatelet therapy adherence remained the same in the E-ZES
and C-SES groups (79.6% at 1 year, 32.8% at 2 years, and 21.6% at 3 years). We observed a statistically significant
(P ¼ 0.0052) heterogeneity in treatment effect of stent type in relation to DAPT. In the absence of DAPT, stent throm-
bosis was lower with E-ZES vs. C-SES (adjusted hazard ratio 0.38, 95% confidence interval 0.19, 0.75; P ¼ 0.0056). In the
presence of DAPT, no difference was found (1.18; 0.79, 1.77; P ¼ 0.43).
Conclusion A strong interaction was observed between drug-eluting stent type and DAPT use, most likely prompted by the vascular
healing response induced by the implanted DES system. These results suggest that the incidence of stent thrombosis in
DES trials should not be evaluated independently of DAPT use, and the optimal duration of DAPT will likely depend upon
stent type (Clinicaltrials.gov number NCT00476957).
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Introduction
The importance of dual antiplatelet therapy (DAPT) to prevent
in-stent thrombotic events in patients implanted with a drug-eluting
stent (DES) has been widely reported.1– 3 Interruption of DAPT is
also a major independent predictor of stent thrombosis,4 underscor-
ing the importance of this therapy in the prevention of early and late
thrombotic events after deployment of a DES.
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The Patient RelatedOuTcomeswith Endeavor vs.Cypher stenting
Trial (PROTECT)5 was designed as a superiority trial comparing the
incidence of stent thrombosis in a broad population of patients and
involving two widely used DES with different potency profiles and
nearly opposite healing characteristics: the Endeavor zotarolimus-
eluting stent (E-ZES; Medtronic CardioVascular) and the Cypher
sirolimus-eluting stent (C-SES; Cordis, Johnson & Johnson).6,7 Both
devices prevent the occurrence of restenosis yet have different
antiproliferative potencies due to drug, polymer, and drug-release
characteristics.8 Therefore, the key design element of PROTECT
was the selection of two DES systems with contrasting site-specific
vascular healing responses, with E-ZES more closely mirroring the
healing response following bare-metal stent implantation.6,7
In PROTECT, the primary outcome of definite or probable stent
thrombosis at 3 years did not differ between E-ZES and C-SES
[1.42% (predicted 1.5%) vs. 1.79% (predicted 2.5%); log-rank
P ¼ 0.22], respectively.9 During the period from 1 to 3 years when
the use of DAPT was low, however, a significant 0.75% difference
emerged in the incidence of stent thrombosis (E-ZES 0.32% vs.
C-SES 1.07%; log-rank P, 0.0001). We hypothesized that DAPT
use influenced the rate of stent thrombosis to a different extent,
depending upon the type of implanted DES.
Methods
PROTECT is a two-arm, multinational superiority trial, with a prospect-
ive randomized open-label blinded-endpoints design.5 The trial involved
196 centres in 36 countries across five continents. Patients were rando-
mized 1 : 1 to E-ZES or C-SES and mandated to undergo an electrocar-
diogram at 3-year follow-up. Source documentation of all events was
100% monitored. Other data monitoring was performed in 30% of ran-
domly selected patients at all centres.
Patients provided informed consent to participate. The protocol was
approved by the institutional ethical committee and/or centralized na-
tional ethical board according to the rules specific to the country.
Stent thrombosis (definite or probable) was defined according to the
Academic Research Consortium definitions.10 In accordance with the
main results paper,9 the composite of definite or probable stent throm-
bosis at 3 years was the primary endpoint and definite stent thrombosis
the secondary endpoint. Dual antiplatelet therapy was defined as the
combination of aspirin plus clopidogrel or ticlopidine (both pro-drugs
metabolized in the liver) and no DAPT (‘off-DAPT’) was defined as
either single antiplatelet (aspirin or clopidogrel/ticlopidine) or no antipla-
telet therapy.
Statistical methods
We systematically analysed if (and to what extent) DAPT use modified
the effect of stent type on the primary and secondary endpoints.
Follow-up visits were scheduled up to 36 months, and information on
actual DAPT use was collected. We calculated cumulative patient-years
of follow-up in relation to DAPT exposure. The ‘on’/‘off’ DAPT status at
each visit determined the status for the period between this and the next
visit. Thus, an individual could potentially contribute to patient-years ‘on’
as well as ‘off’ DAPT, and any treatment change was taken into account.
We report the number of patients who reached a study endpoint relative
to the cumulative patient-years of follow-up in relation to DAPT expos-
ure (i.e. DAPT-specific incidence rates). We do not report multiple
events per patient and follow-up time was not counted after a study end-
point was reached.
Univariate Cox proportional hazard regression models were fitted,
with stent thrombosis as the outcome and stent treatment and DAPT
use as the determinants. We defined DAPT use as a time-dependent cov-
ariate, in agreement with the definition described above. Multivariable
Cox models were subsequently fitted, and the following variables were
considered as potential covariates: age, medical history (diabetes melli-
tus, cigarette smoking, prior myocardial infarction, or stroke), serum cre-
atinine, stent length and diameter, overlapping stents, lesion
characteristics, assigned treatment (E-ZES vs. C-SES), and a time-
dependent covariate for DAPT. To avoid over-fitting the model, the
number of covariates (i.e. the associated degrees of freedom) was
limited to 1 for each 10 incident endpoints. Covariates with the lowest
P-values in univariate analysis were selected. We then applied the
backward-deletion model reduction strategy so that in the final model
all covariates had a P-value ,0.15. The final multivariable model was
enriched with the interaction term ‘stent-treatment * DAPT’ (as the
time-dependent covariate).
P-values of ,0.05 were considered statistically significant and no
formal adjustment was made for multiple testing. Analyses were per-
formed using SAS, version 9.2.
Results
Between 21 May 2007 and 22 December 2008, 8791 patients were
identified, of which 8709 provided consent and were eligible for in-
clusion: 4357 patients were randomized to E-ZES and 4352 to
C-SES. Data for 8340 (95.8%) patients were available at 3-year
follow-up.
The groups were similar in terms of their clinical characteristics.
Lesion characteristics revealed more lesions treated in the main
stem and in the right coronary as well as calcified lesion in the
C-SES group; procedural characteristics revealed a greater number
of stents per lesion and overlapping stents, and lower use of predila-
tation in the E-ZES group (Table 1).
Dual antiplatelet therapy and stent type as
determinants of stent thrombosis
Incidence and incidence rate of stent thrombosis are shown in
Table 2. Adherence to DAPT at day 30 and at all follow-up intervals
up to 3 years was similar in both groups (Table 3 and Figures 1 and
2). ‘Off-DAPT’ patients were evenly distributed among aspirin
alone, thienopyridine alone, and no DAPT up to 3 years in both
groups, with the exception of a slightly higher use of thienopyridine
in the E-ZES group at 1 year (Table 3). Cumulative follow-up patient-
years in the presence (‘on-DAPT’) or absence (‘off-DAPT’) of DAPT
according to stent type were also similar (Figure 1 and 2 subtables).
A statistically significant heterogeneity was observed in treatment
effect of stent type in relation to DAPT use for definite or probable
stent thrombosis (P ¼ 0.0052) and for definite stent thrombosis
(P ¼ 0.012). Figure 3 and Table 4 summarize the outcomes of the
interaction between DAPT and stent type on the incidence of stent
thrombosis. From the perspective of DAPT use, no significant
DAPTeffect was observed in E-ZES patients in terms of the incidence
rate of stent thrombosis, whereas a significant effect was seen in
C-SES patients. From the perspective of stent type, off-DAPT the in-
cidence rate and incidence for both definitions of stent thrombosis at
3 years (1080 days) were lower with E-ZES than with C-SES (Table 2,
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Age, years 62.3+10.6 62.1+10.7 0.50
Male sex 76.7 76.0 0.48
Body mass index, kg/m2 27.8+4.4 27.9+4.5 0.24
Diabetes mellitus 26.9 28.4 0.13
Insulin dependent 6.5 7.4 0.11
Hypertension 64.6 63.4 0.26
Hyperlipidaemia 61.8 62.8 0.34
History of smoking 57.7 57.4 0.80
Current smoker 24.9 25.2 0.71
Premature coronary artery disease in first-degree relative (n ¼ 7540) 34.2 34.8 0.59
Previous myocardial infarction 20.3 20.8 0.53
Previous CABG 4.6 5.1 0.21
Previous PCI 12.3 12.8 0.48
Previous stroke 3.1 3.1 0.85
Procedure indication
All (acute) myocardial infarctions 25.8 26.0 0.85
ST-elevation 8.2 8.8 0.28
Non-ST-elevation 17.6 17.1 0.57
Unstable angina 18.3 19.3 0.21
Stable angina 49.5 48.3 0.27
Silent ischaemia 6.5 6.4 0.93
Left ventricular ejection fraction (%) (n ¼ 4489) 58.8+12.6 58.3+12.6 0.17
Serum creatinine (mmol/L) (n ¼ 8152) 87.6+31.5 88.3+38.4 0.37
Complex patientsa 58.0 58.1 0.93
Lesion characteristics
Vessel location (by patient)
Left anterior descending 58.0 56.4 0.13
Left circumflex 28.9 28.6 0.76
Right coronary artery 32.4 34.7 0.026
Left main 0.9 1.4 0.047
Bypass graft 0.3 0.4 0.49
In-stent restenosis 2.2 2.2 1.00
Chronic total occlusionb 3.4 3.6 0.69
Bifurcation 21.9 20.5 0.10
Moderate/severe calcification ( vs. none or mild) 30.1 32.4 0.018
Tortuosity: moderate or severe ( vs. mild) 26.0 25.7 0.83
Presence of thrombus ( vs. none) 9.9 10.4 0.52
Procedure characteristics
Number of vessels treated per patient 1.20+0.45 1.20+0.46 0.46
Number of lesions treated per patient 1.40+0.71 1.39+0.71 0.85
Number of stents per patient 1.63+0.99 1.59+0.96 0.06
Total stent length/patient (mm) 31.28+20.80 31.20+20.77 0.86
Number of stents per lesion 1.16+0.49 1.13+0.46 0.001
≥1 stent ≤2.75 mm in diameter (%) 44.3 46.2 0.077
≥1 overlapping stent (%) 15.8 13.2 ,0.001
Lesions with predilatation 67.5 69.4 0.023
Periprocedure medication
Unfractionated heparin 92.1 92.0 0.91
Continued
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Figures 1A and 2A) whereas no difference was found on-DAPT
(Table 2, Figures 1B and 2B).
Further determinants of stent thrombosis
Independent predictors of stent thrombosis (Table 4) show a similar
pattern to the univariate predictors (Table 2, Appendix 2), with
diabetes mellitus, ≥1 stent ≤2.75 mm in diameter, and current
smoking being strongly significant for both definitions of stent
thrombosis.
Discussion
These data from PROTECT suggest that adherence to DAPT modi-
fies the outcome of stent thrombosis to a greater extent after C-SES
deployment than after E-ZES deployment, most likely due to differ-
ential healing characteristics. These findings suggest that DAPT use
should be taken into consideration when interpreting the incidence
of stent thrombosis in studies evaluating different DES.
Irrespective of the definition of stent thrombosis used (i.e. definite
or probable or definite alone) a highly significant interaction was
observed between DES type and DAPT use. From the perspective
of stent type, this interaction revealed a higher incidence and inci-
dence rate of stent thrombosis in the C-SES arm off-DAPT. Con-
versely, in patients on-DAPT, both stent types showed a similar
incidence and incidence rate of stent thrombosis. This analysis did
not evaluate a differentiated effect of either single antiplatelet vs.
no antiplatelet therapy or different types of single antiplatelet therap-
ies. From earlier literature one can assume that the less potent the
antiplatelet regimen the higher the incidence of stent thrombosis.11
Thus, the current analysis comparing the influence of a standard
DAPT regimen with a pooled mix of single or no antiplatelet
therapy may have attenuated the current findings between E-ZES
and C-SES.
The risk assessment expressed as cumulative incidence rate shows
a greater sensitivity to detect safety signals off-DAPT. Further, the cu-
mulative incidence curves for definite/probable and definite stent
thrombosis for E-ZES vs. C-SES start to separate at 18 months
(540 days) and continue to diverge up to 1080 days. Conversely,
while on-DAPT, the incidence curves of stent thrombosis for both
stent types remain close, running almost parallel from 720 days








Low-molecular-weight heparin 5.0 5.4 0.38
Direct thrombin inhibitor 4.2 3.8 0.44
Glycoprotein IIb/IIIa inhibitor 17.9 18.4 0.60
Data given as percentage or means+ standard deviation.
aDefined as placement of a stent in a patient with at least one of the following clinical or lesion characteristics: renal insufficiency [creatinine level:≥140mmol/L (1.6 mg/dL)], ejection
fraction:,30%, acute myocardial infarction ≤72 h,.1 lesion per vessel,.2 vessels with stents, lesion length.27 mm, bifurcation lesion, lesion in bypass graft, in-stent restenosis,
unprotected left main artery, lesion with thrombus, or total occlusion.22
CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.
bThrombolysis in myocardial infarction (TIMI) 0; no unstable angina; no myocardial infarction.
C-SES, Cypher sirolimus-eluting stent; E-ZES, Endeavor zotarolimus-eluting stent.
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Table 2 Incidence and incidence rate of definite or probable and definite stent thrombosis at 1080 days
Definite or probable stent thrombosis Definite stent thrombosis
Incidencea n (%) Incidence rateb 31022 Incidencea n (%) Incidence rateb 31022
Overall 136/8340 (1.6) 0.5 (136/25 017) 82/8340 (1.0) 0.3 (82/25 017)
E-ZES 61/4181 (1.5) 0.5 (61/12 535) 31/4181 (0.7) 0.2 (31/12 535)
C-SES 75/4159 (1.8) 0.6 (75/12 482) 51/4159 (1.2) 0.4 (51/12 482)
E-ZES off-DAPT 11/4181 (0.3) 0.2 (11/4573) 3/4181 (0.1) 0.1 (3/4573)
C-SES off-DAPT 31/4159 (0.8) 0.7 (31/4553) 19/4159 (0.5) 0.4 (19/4553)
E-ZES on-DAPT 50/4181 (1.2) 0.6 (50/7962) 28/4181 (0.7) 0.4 (28/7962)
C-SES on-DAPT 44/4159 (1.1) 0.6 (44/7928) 32/4159 (0.8) 0.4 (32/7928)
Off-DAPT 42/8340 (0.5) 0.5 (42/9126) 22/8340 (0.3) 0.2 (22/9126)
On-DAPT 94/8340 (1.1) 0.6 (94/15 891) 60/8340 (0.7) 0.4 (60/15 891)
C-SES, Cypher sirolimus-eluting stent; DAPT, dual antiplatelet therapy; E-ZES, Endeavor zotarolimus-eluting stent.
aIncidence: number of events/number of patients randomized to either E-ZES, C-ZES, or all. Dual antiplatelet therapy status is not taken into account in the denominator.
bIncidence rate: number of events/number of follow-up years.
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Table 3 Use of antiplatelet therapy (aspirin, clopidogrel, or ticlopidine) from day 30 to 3 years at exact time points of
follow-up
E–ZES stent (n5 4357) C–SES stent (n 5 4352) Difference (95% confidence interval) P-value
At 30 days
DAPTa 4110 (94.3) 4112 (94.5) –0.2 (–1.1, 0.8) 0.78
No DAPT: 247 (5.7) 240 (5.5) 0.2 (20.8, 1.1) 0.78
Aspirinb 72 (1.7) 77 (1.8) –0.1 (–0.7, 0.4) 0.68
Thienopyridinec 109 (2.5) 114 (2.6) –0.1 (–0.8, 0.5) 0.74
Noned 66 (1.5) 49 (1.1) 0.4 (–0.1, 0.9) 0.13
At 180 days
DAPTa 4040 (92.7) 4006 (92.0) 0.7 (–0.4, 1.8) 0.24
No DAPT: 317 (7.3) 346 (8.0) 20.7 (21.8, 0.4) 0.241
Aspirinb 124 (2.8) 142 (3.3) –0.4 (–1.1, 0.3) 0.26
Thienopyridinec 109 (2.5) 97 (2.2) 0.3 (–0.4, 0.9) 0.44
Noned 84 (1.9) 107 (2.5) –0.5 (–1.1, 0.1) 0.09
At 360 days
DAPTa 3468 (79.6) 3459 (79.5) 0.1 (–1.6, 1.8) 0.89
No DAPT: 889 (20.4) 893 (20.5) 20.1 (–1.8, 1.6) 0.89
Aspirinb 594 (13.6) 624 (14.3) –0.7 (–2.2, 0.8) 0.35
Thienopyridinec 149 (3.4) 111 (2.6) 0.9 (0.2, 1.6) 0.02
Noned 146 (3.4) 158 (3.6) –0.3 (–1.1, 0.5) 0.48
At 540 days
DAPTa 1728 (39.7) 1695 (38.9) 0.7 (–1.3, 2.8) 0.50
No DAPT: 2629 (60.3) 2657 (61.1) 20.7 (–2.8, 1.3) 0.497
Aspirinb 2238 (51.4) 2270 (52.2) –0.8 (–2.9, 1.3) 0.47
Thienopyridinec 147 (3.4) 144 (3.3) 0.1 (–0.7, 0.8) 0.91
Noned 244 (5.6) 243 (5.6) 0.0 (–0.9, 1.0) 1.00
At 720 days
DAPTa 1430 (32.8) 1424 (32.7) 0.1 (–1.9, 2.1) 0.93
No DAPT: 2927 (67.2) 2928 (67.3) 20.1 (–2.1, 1.9) 0.93
Aspirinb 2450 (56.2) 2455 (56.4) –0.2 (–2.3, 1.9) 0.88
Thienopyridinec 162 (3.7) 155 (3.6) 0.2 (–0.6, 0.9) 0.73
Noned 315 (7.2) 318 (7.3) –0.1 (–1.2, 1.0) 0.90
At 900 days
DAPTa 1220 (28.0) 1241 (28.5) –0.5 (–2.4, 1.4) 0.60
No DAPT: 3137 (72.0) 3111 (71.5) 0.5 (–1.4, 2.4) 0.60
Aspirinb 2555 (58.6) 2544 (58.5) 0.2 (–1.9, 2.3) 0.86
Thienopyridinec 174 (4.0) 172 (4.0) 0.0 (–0.8, 0.9) 0.96
Noned 408 (9.4) 395 (9.1) 0.3 (–0.9, 1.5) 0.66
At 1080 days
DAPTa 919 (21.1) 959 (22.0) –0.9 (–2.7, 0.8) 0.29
No DAPT: 3438 (78.9) 3393 (78.0) 0.9 (20.8, 2.7) 0.29
Aspirinb 2142 (49.2) 2097 (48.2) 1.0 (–1.1, 3.1) 0.37
Thienopyridinec 146 (3.4) 148 (3.4) –0.0 (–0.8, 0.7) 0.91
Noned 1150 (26.4) 1148 (26.4) 0.0 (–1.8, 1.9) 1.00
aDAPT: aspirin plus thienopyridine (clopidogrel or ticlopidine).
bAspirin only (thienopyridine stopped).
cThienopyridine only (aspirin stopped).
dBoth thienopyridine and aspirin stopped.
C-SES, Cypher sirolimus-eluting stent; E-ZES, Endeavor zotarolimus-eluting stent.
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Figure 1 Cumulative incidence of definite or probable stent thrombosis and mean prevalence (A) off-dual antiplatelet therapy and (B) on-dual
antiplatelet therapy in Endeavor zotarolimus-eluting stent and Cypher sirolimus-eluting stent groups. C-SES, Cypher sirolimus-eluting stent;
DAPT, dual antiplatelet therapy; E-ZES, Endeavor zotarolimus-eluting stent.
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Figure 2 Cumulative incidence of definite stent thrombosis and mean prevalence (A) off-dual antiplatelet therapy and (B) on-dual antiplatelet
therapy in Endeavor zotarolimus-eluting stent and Cypher sirolimus-eluting stent groups. C-SES, Cypher sirolimus-eluting stent; DAPT, dual anti-
platelet therapy; E-ZES, Endeavor zotarolimus-eluting stent.
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onwards, revealing little sensitivity to detect stent-thrombosis-
related safety signals and thus having similar long-term stent-
thrombosis-related safety profiles. Thus, the incidence of stent
thrombosis over time was distributed differentially according to
DAPT-adherence pattern: off-DAPT the difference started to
emerge after 18 months; on-DAPT both devices had a very similar
Figure3 Riskof (A) definite or probable or (B) definite stent thrombosis up to 1080 days according to drug-eluting stent-type and dual antiplatelet
therapy-use. C-SES, Cypher sirolimus-eluting stent; DAPT, dual antiplatelet therapy; E-ZES, Endeavor zotarolimus-eluting stent.
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Table 4 Multivariable predictors of stent thrombosis
Predictor Definite or probable
stent thrombosis (n 5 136)
Definite
stent thrombosis (n 5 82)
HR (95% CI) P-value HR (95% CI) P-value
E-ZES vs. C-SES in patients off-DAPT 0.38 (0.19, 0.75) 0.0056 0.16 (0.05, 0.56) 0.0037
E-ZES vs. C-SES in patients on-DAPT 1.18 (0.79, 1.77) 0.43 0.89 (0.53, 1.47) 0.64
DAPT in patients randomized to E-ZES 0.86 (0.39, 1.87) 0.70 2.52 (0.70, 9.15) 0.16
DAPT in patients randomized to C-SES 0.27 (0.15, 0.51) ,0.0001 0.47 (0.22, 0.99) 0.047
Diabetes mellitus 1.88 (1.33, 2.67) 0.0004 1.78 (1.14, 2.78) 0.012
≥1 stent ≤2.75 mm in diameter 1.93 (1.33, 2.80) 0.0006 1.96 (1.23, 3.12) 0.0044
Smoked cigarette within past 90 days 1.79 (1.23, 2.61) 0.0024 1.77 (1.11, 2.80) 0.016
Prior myocardial infarction 1.54 (1.07, 2.23) 0.021 — .0.15a
≥1 lesion with thrombus 1.72 (1.07, 2.76) 0.025 — .0.15a
≥1 lesion with calcification (moderate/severe) 1.41 (1.00, 2.00) 0.052 1.50 (0.96, 2.33) 0.08
Prior stroke 1.91 (0.96, 3.77) 0.06 — .0.15a
Serum creatinine concentration (mmol/L) 1.00 (1.00, 1.01) 0.06 — .0.15a
Age ≥75 years 1.53 (0.97, 2.41) 0.07 — .0.15a
Total stent length per patient (mm) 1.01 (1.00, 1.01) 0.10 — .0.15a
≥1 overlapping stent 1.42 (0.90, 2.23) 0.13 1.74 (1.05, 2.89) 0.032
CI, confidence interval; DAPT, dual antiplatelet therapy; HR, hazard ratio.
aVariable did not meet the criteria (P-value ,0.15) to stay in the multivariable model.
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incidence of (early and) very late stent thrombosis, but E-ZES had a
numerically higher incidence of late stent thrombosis (. 30 days
to 1 year). Pathophysiologically, a less DAPT-dependent mechanism
seems to play a role in E-ZES late events and a more
DAPT-dependent mechanism in C-SES very late events (.1 year),
suggesting different mechanisms of stent occlusion (i.e. occlusive re-
stenosis in the E-ZES group vs. thrombotic occlusion secondary to
delayed healing and/or plaque rupture in the context of
neo-atherosclerosis12 in the C-SES group).
Because almost all the patients were on-DAPT during the first
year, we looked at the period after 360 days (very late), when adher-
ence started to drop ,80% and thus the cumulative follow-up
patient-years off-DAPT started to increase substantially as did the
rate of events. We found that 3350 cumulative patient-years
off-DAPT per group would have provided the protocol-mandated
statistical power of 90%5 to reveal a coherent safety signal between
the two stent systems according to the primary endpoint, represent-
ing slightly over 1.5 years.
From the perspective of DAPT use, patients randomized to E-ZES
showed no significant DAPT effect on the incidence of stent throm-
bosis up to 3 years, whereas a significant effect could be demon-
strated in the C-SES group. Therefore, the ‘DAPT effect’ is more
apparent after deployment of the potent C-SES DES, inducing a
longer-termalteredhealing response, and reflectingbothapersistent
in-stentpro-thrombotic environment and a likelyneed for prolonged
antithrombotic administration. Not unexpectedly other strong uni-
variate and multivariable predictors of stent thrombosis, which
could guide tailoring DAPT duration on an individual basis, were
also related—at least in part—to stent or vessel-healing properties.
Patients with multiple characteristics that alter vessel recovery and
favour persistency of a site-specific in-stent pro-thrombotic milieu
are likely to need a more prolonged duration of DAPT. Of interest,
in this context, the strongest criterion to pursue long-term thrombo-
protective DAPT was diabetes mellitus.
The strong interaction between the treatment modalities ‘DES
type’ and ‘DAPT use’, an aspect linked to clinical trial methodology
neglected thus far, may also be relevant when re-evaluating the litera-
ture on DES. The key points are the following:
First, the period off-DAPT shows a greater sensitivity to detect
safety signals after DES deployment. Therefore, long-term follow-
up (with sufficient events and patient-years) is essential to ensure
sufficient off-DAPT time to detect a difference between DES
types. This is particularly true in randomized trials in which DAPT
duration is not mandated in the protocol, as demonstrated in the
primary analysis from PROTECT.9 When DAPT duration is man-
dated but DAPT use at follow-up is missing and a balanced use
of DAPT among groups can be assumed, long-term follow-up
remains essential to detect safety signals, as demonstrated in the
3-year follow-up of SORT OUT III—a trial similar by design to
PROTECT, and using an administrative-guided clinical endpoint.13
Not surprisingly, the first long-term safety signals became apparent
in the very first trials in which duration of DAPT was defined and
when physicians were not aware of the risk of late or very late
thrombotic events.14 – 16
Second, high adherence to DAPT prevents a reliable evaluation of
the safety profiles of stent systems as assessed by the incidence of
stent thrombosis. Therefore, randomized trials with short follow-up
(up to 1 year) and high adherence to DAPT over the study-period
have limited validity to determine long-term safety profiles of study
stents using stent thrombosis as a criterion.17– 25 One should not
neglect, however, the impactof stent thrombosis secondary toocclu-
sive restenosis23–25—a less ‘DAPT-dependent’ phenomenon—as a
confounding factor during the first year.
Third, apparent differences in the safety profiles of DES may be due
to imbalances in use of DAPT across study arms. Therefore, clinical
evaluations (e.g. in sequential registries or meta-analyses) of DES
systems with different adherence to DAPT or that do not factor in
DAPT effect will be limited in terms of their ability to evaluate DES
safety profiles using the stent-thrombosis criterion.26,27
Fourth, the healing characteristics associatedwith stent systems in-
fluence the thromboprotective efficacy of DAPT, as shown in this
analysis. Therefore, pooling data from different DES types28– 33 or
DAPT regimens,34 or determination of a generalized optimal dur-
ation of DAPT after DES deployment,28,30,32 without taking into
account the specific biological attributes of each stent system will
not provide a clinically valuable message. Conversely, the evaluation
of a specific stent system for different durations of DAPT is clinically
meaningful, but generalization of the stent-specific finding to other
DES types should be avoided.35,36
To put this analysis of the 3-year results of PROTECT into per-
spective, we searched Medline for randomized trials that analysed
the interaction of DES type and DAPT use in relation to clinical
events. We found PRODIGY,37 which explored prospectively in
2013 patients randomized in a4-by-2 design to four stent types (bare-
metal, zotarolimus-eluting, paclitaxel-eluting, and everolimus-eluting)
and two different durations of DAPT (6 vs. 24 months). The primary
endpoint was a composite of death, myocardial infarction, or cere-
brovascular accident; the secondary endpoint was stent thrombosis.
The authors observed heterogeneity across stent types driven by: an
improved primary endpoint as well as a lower incidence of stent
thrombosis after short-term DAPT in the zotarolimus arm (corre-
sponding to E-ZES in PROTECT); and a higher incidence of stent
thrombosis after short-term DAPT in the paclitaxel-eluting arm.
They concluded, similar to the current analysis, that the optimal dur-
ation of DAPT may be stent-specific. However, no satisfactory
answer to the pathophysiological mechanisms underlying this obser-
vation could be given.
An interaction betweenstent type and DAPT is likely to be present
and to persist in any stent system until vascular recovery has been
achieved; therefore this interaction will be clinically more important
with stent systems associated with a more delayed vascular healing
and/or accelerated atherosclerotic process. Novel stent technolo-
gies have been developed to improve the healing characteristics,
but we will have to wait for the results of the Dual Antiplatelet
Therapy Study,32 if analysed according to stent type, to demonstrate
that conceptual technological modifications have translated into a
long-term decrease of thrombotic events.
Study limitations
While C-SES is no longer available, the two stents, through their bio-
logical diversity, define a ‘wide therapeutic range’. As such they give a
broader validity than a single stent type. Despite randomization, the
groups were not matched exactly, most likely due to the play of
chance, and two of the baseline characteristics affected were
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independent predictors of stent thrombosis; however, the imbalance
was evenly distributed between the two groups, with moderate/
severe calcification more frequent in C-SES and ≥1 overlapping
stent more frequent in E-ZES. Furthermore, the analysis determined
the relation between DAPT use, DES type, and stent thrombosis,
adjusting for potential confounders. The results are unlikely there-
fore to be biased by the imbalance. The mean lost to follow-up
rate is ,5% (4.2%) in PROTECT and the mean incidence of the
primary endpoint (definite or probable stent thrombosis) is 1.6%.
Hence, one may argue that the lost to follow-up may have influenced
the outcome. Baseline characteristics of the lost to follow-up
group—with the exception of serum creatinine concentration—as
well as the criteria identified as predictors of stent thrombosis did
not differ between the E-ZES and C-SES groups (Table 3, Appendix)
and thus it is unlikely that the lost to follow-up group influenced the
endpoint of stent thrombosis in a differential manner. This analysis
focuses on stent thrombosis and predictors of this event, and not
on the clinical sequelae of stent thrombosis. Patients were not rando-
mized to different durations of DAPT so a specific duration of DAPT
use according to DES type cannot be derived. In the off-DAPT group,
at 1 year a lower use of thienopyridine alone was observed in the
C-SES group compared with the E-ZES group; however, the cumula-
tive use of single antiplatelet therapy (aspirin alone or thienopyridine
alone) was close to equal, and no difference in the incidence of stent
thrombosis in the following 6-month time-window was observed.
Lastly, the analysis is post hoc; even though the results are statistically
sound due to the size of the trial and the broad inclusion criteria the
conclusions have to be considered as hypothesis generating.
Conclusion
A strong interaction was observed between DES type and DAPT use,
most likely prompted by the vascular healing response induced by the
implanted DES system and determining a DES type-specific long-
term need for DAPT adherence.
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Appendix 1 PROTECT investigators
Country (patients enrolled) Site Investigator
Argentina (n ¼ 6) Hospital Italiano Regional del Sur C Alvarez
Sanatorio Otamendi A Rodriguez
Australia (n ¼ 414) Southern Health, Monash Medical Center I Meredith
St Vincent’s Sydney D Muller
St Vincent’s Melbourne R Whitbourn
Royal Adelaide S Worthley
Fremantle A Whelan
The Prince Charles Hospital D Walters
Royal Perth Hospital S Shetty
Box Hill Hospital G New
The Wesley Hospital S Cox
Gold Coast Hospital R Batra
Northern Hospital W van Gaal
John Hunter Hospital G Bellamy
Austria (n ¼ 144) Landesklinikum St Po¨lten H Mayr
Salzburger Landeskliniken M Heigert
Wilhelminensp der Stadt Wien K Huber
AKH Linz F Leisch
Belgium (n ¼ 265) OLVrouwziekenhuis W Wijns
UZ Leuven (Gasthuisberg) W Desmet
CHR Citadelle J Boland
Cliniques Universitaires UCL E Schroeder / P Chenu
CHU Sart-Tilman V Legrand
Canada (n ¼ 52) Ottawa Heart Institute M Labinaz
London Health Sciences Center P Teefy
Hoˆpital Laval O Bertrand
China (n ¼ 252) Beijing Fuwai Hospital R Gao
Zhongshan Hospital Fudan Univ J Ge
Czech Republic (n ¼ 19) Faculty Hospital Brno Bohunice P Kala
Mas Hospital Usti nad Labem P Cervinka
Dominican Republic (n ¼ 44) CEDIMAT P Uren˜a
Finland (n ¼ 29) Kuopio University Hospital J Hartikainen
France (n ¼ 952) AP C Bernard - Hoˆpital Bichat G Steg
Clinique Pasteur J Fajadet
CHU Rangueil - Toulouse D Carrie
Hoˆpital de la Cavale Blanche M Gilard
Polyclinique des Fleurs P Barragan
CHU Lille J-M Lablanche
Clinique Saint-Hilaire R Koning
Hoˆpital Charles Nicolle-CHU H Eltchaninoff
Clinique Saint Augustin O Darremont
Polyclinique de la Louvie`re F Leroy
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Country (patients enrolled) Site Investigator
CHU Michallon - Grenoble B Bertrand
Clinique Saint- Pierre G Robert
CHU Jean Minjoz - Besancon F Schiele
Clinique Saint-Gatien S Chassaing
Nouvelles Cliniques Nantaises E Bressollette / P Brunel
Hoˆpital Trousseau - CHU L Quilliet
Clinique Rhone-Durance J Brunet
Hoˆpital Henri Duffaut M Pansieri
AP Lariboisiere G Sideris / V Stratiev
AP Henri Mondor E Teiger
Hoˆpital Pontchaillou - Rennes H Lebreton
Hoˆpital La Timone J-L Bonnet
Clinique Saint Martin B Karsenty
CH Pau N Delarche
CHU Clermont Ferrand J-R Lusson / J Cassagnes
Germany (n ¼ 1369) Klinikum Coburg J Brachmann
Universita¨tsklinikum Lu¨beck V Kurowski
M Luther UnivKlin Kro¨llwitz M Buerke
Med Hochschule Hannover B Schieffer
Herz- und Diabeteszentrum W Scholtz / M Wiemer
Klinikum der J W Goethe Univ S Fichtlscherer / V Scha¨chinger
Klinikum der Univ Mu¨nchen Großhadern C Kupatt / P Boekstegers
Klinikum der J Gutenberg Univ S Genth-Zotz
Universita¨tsklinikum Freiburg C Bode
Universita¨tsklinikum Heidelberg N Frey
Herz Zentrum Bad Krozingen F-J Neumann
Charite´ - Campus B Franklin B Witzenbichler / K Pels
Herzzentrum Dresden R Strasser
Asklepios Klinik St Georg K-H Kuck
Krankenh der Barmh Bru¨der K-E Hauptmann
Univ Klinikum Hamburg-Eppendorf S Baldus / T Heitzer
Lukas Krankenhaus M Haude
Klinikum Bogenhausen E Hoffmann
Klinikum Villingen-Schwenningen W Jung
Vivantes Klin im Friedrichshain S Hoffmann
Sta¨dtisches Klinikum Karlsruhe C Schmitt
Vivantes Humboldt-Klinikum M Dissmann
Klinikum Nu¨rnberg M Pauschinger
Sta¨dtische Kliniken Darmstadt G Werner
University Magdeburg R Braun-Delleus
Marienhof Koblenz D Burkhardt / M Manz
Greece (n ¼ 55) Onassis Cardiac Surgery Center V Voudris
1st IKA D Sionis
Hong Kong (n ¼ 59) Queen Elizabeth Hospital M-L Kang-Yin
Pamela Youde Nethersole Eastern Hospital T-S Tse
Hungary (n ¼ 107) Semmelweis University B Merkely
India (n ¼ 506) Jaslok Hospital & Res Centre A Mehta
The Heart Care Clinic K Parikh
Max Heart and Vascular Institute V Kumar / P Chandra
Apollo Hospital, Hyderabad P Rath
Ruby Hall Clinic S Hiremath
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Ireland (n ¼ 33) St James’ Hospital P Crean
University Hospital Galway K Daly
Israel (n ¼ 64) Rabin Med Center, Belinson Campus R Kornowski
Rambam Medical Center A Kerner
Meir MC M Mosseri
Barzilay MC G Jafari
Italy (n ¼ 123) Az Osp S Giovanni di Dio e Ruggi D’Aragona P Giudice
Policlinico "A Gemelli" C Trani
Ospedale S Maria Nuova A Manari
Ospedale S Giovanni - Addolorata F Prati
Ospedale Lancisi A Pangrazi
S Donato USL 8 L Bolognese
(South) Korea (n ¼ 254) Chonnam University Hospital M-H Jeong
Dong-A University Hospital M-Y Kim
Seoul Nat Univ Hospital H-S Kim
ASAN Medical Center S-J Park
Latvia (n ¼ 126) P Stradins University Hospital A Erglis
Hospital "Gailezers" A Kalnins
Luxembourg (n ¼ 1) INCCI D Wagner
Malaysia (n ¼ 74) National Heart Institute (IJN) R Zambahari
Sarawak General Hospital T-K Ong / K Sim
Netherlands (n ¼ 535) Amphia Ziekenh Molengracht P den Heijer
VU Medisch Centrum Y Appelman
St Antonius Ziekenhuis M-J Suttorp
Univ Med Centrum Groningen B de Smet
Catharina Ziekenhuis J Koolen
Univ Medisch Centrum Utrecht P Stella
New Zealand (n ¼ 85) Wellington Hospital S Harding
Ascot Integrated Hospital J Warwick / A Maslowski
Wakefield Hospital M Abernethy
Waikato Hospital G Devlin
Norway (n ¼ 34) Haukeland Universitets Sykehus S Rotevatn
Feiringklinniken Y Myreng
Poland (n ¼ 86) SPSK No1, ACK AMG D Ciecwierz
WSS imdr WlBieganskiego J Peruga
4 Wojskowy Szpital Kliniczny K Reczuch
Portugal (n ¼ 177) Hospital Santa Cruz R Campante Teles
Hospital Fernando Fonseca P Farto E Abreu
Centro Hospital de Coimbra A Leita˜o-Marques
Hospital Garcia Orta H Pereira
Romania (n ¼ 54) Univ Hospital of Bucharest D Vinereanu
Saudi Arabia (n ¼ 262) Prince Sultan Cardiac Center S Alkasab
King Fahd Medical City H Mhish / M Al Kurdi
King Faisal Specialist Hospital F Al Turki
Singapore (n ¼ 34) National Heart Center P Wong
National University Hospital S-G Teo
Spain (n ¼ 328) Hospital Puerta de Hierro F-J Goicolea Ruigomez
Hospital Vı´rgen de la Arrixaca M Valde´s Cha´varri
Hospital de Son Dureta A Bethencourt Gonzalez
Hospital de Meixoeiro A In˜iguez Romo
Hospital Infanta Cristina J Lo´pez Minguez
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Country (patients enrolled) Site Investigator
Hospital Clı´n Univ V Victoria J-M Herna´ndez Garcı´a
Hospital Juan Ramo´n Jime´nez J Diaz Ferna´ndez
Hospital Univ V de la Macarena R Ruiz Salmeron
Hospital Univ La Princesa L Martinez Elbal
Hospital Univ Marque´s Valdecilla J Zueco
Hospital de San Juan de Alicante RF Lo´pez-Palop
Hospital Virgen de las Nieves R Melgares
Sweden (n ¼ 201) Centrallasarettet Va¨stera˚s E Diderholm / A Ka˚regren / O Herterich
Universitetssjukhuset i Lund G Olivencrona
Universitetssjukhuset O¨rebro O Fro¨bert
Switzerland (n ¼ 63) Hoˆpitaux Universitaire Gene`ve M Roffi / V Verin
Centre Hospitalier Universitaire Vaudois G Girod
Kantonsspital Aarau AG A Vuilliomenet
Taiwan (n ¼ 66) Chang Gung Memorial Hospital LK I-C Hsieh
Chang Gung Mem Hospital KS C-J Wu
UK (n ¼ 1658) Glenfield Hospital A Gershlick
Papworth Hospital C Densem
Queen Elizabeth Medical Centre S Doshi
Royal Victoria Hospital G Manoharan
King’s College Hospital P McCarthy
James Cook University Hospital M De Belder
Cardiothoracic Centre J Mills
Manchester Royal Infirmary F Fath-Ordoubadi
Southampton General Hospital I Simpson
Leeds General Infirmary J Greenwood
Cheltenham General Hospital R Chamberlain-Webber / Z Khan
New Cross Hospital J Cotton
City General Hospital M Gunning
Morriston D Smith
Royal Bournemouth S Talwar
Royal Sussex County Hospital S Holmberg
Freeman I Purcell
University Hospital of Wales R Anderson
Castle Hill Hospital F Alamgir
Mayday Hospital K Beatt
Basildon Hospital CTC P Kelly
USA (n ¼ 178) Sharp Chula Vista Med Center M Moussavian
Cooper University Hospital J Aji
Ocala Regional Medical Center R Prashad
Dallas VA Medical Center A Zankar / S Banerjee
Bethesda North Hospital S Lewis
AnMed Health B McLaurin
Emory University Hospital J Douglas
Methodist Hospital S Brener
Aurora St Lukes A Gupta
University Hospital - Augusta L Walters
Bridgeport Hospital M Driesman
Baptist Hospital - Pensacola FL R Aycock
Doctors Hospital at Renaissance C Mego
University of Massachusetts D Fisher
Maimonides Medical Center R Frankel
Washington Hospital Center L Satler
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Appendix 2 Table Univariate predictors of stent thrombosis




HR (95% CI) P-value HR (95% CI) P-value
Total stent length per patient (mm) 1.01 (1.01, 1.02) ,0.0001 1.01 (1.01, 1.02) 0.0006
≥1 stent ≤2.75 mm in diameter 2.27 (1.59, 3.24) ,0.0001 2.19 (1.39, 3.46) 0.0007
Diabetes mellitus 1.99 (1.42, 2.80) ,0.0001 1.80 (1.16, 2.80) 0.009
≥1 overlapping stent 2.03 (1.38, 2.99) 0.0003 2.01 (1.22, 3.31) 0.006
≥1 lesion calcification (moderate/severe) 1.71 (1.22, 2.40) 0.002 1.66 (1.07, 2.57) 0.024
Prior myocardial infarction 1.69 (1.17, 2.43) 0.005 1.52 (0.94, 2.46) 0.09
DAPT 0.45 (0.26, 0.80) 0.006 0.79 (0.40, 1.58) 0.51
Prior stroke 2.31 (1.18, 4.55) 0.015 1.67 (0.61, 4.57) 0.32
≥1 lesion with tortuosity (moderate/severe) 1.53 (1.07, 2.18) 0.018 1.00 (0.61, 1.63) 0.98
Serum creatinine concentration (mmol/L) 1.00 (1.00, 1.01) 0.023 1.00 (1.00, 1.01) 0.35
Smoked cigarette within 90 days 1.50 (1.05, 2.14) 0.027 1.57 (0.99, 2.47) 0.054
Age ≥75 years 1.61 (1.04, 2.48) 0.032 1.35 (0.74, 2.43) 0.33
≥1 lesion with thrombus 1.62 (1.02, 2.58) 0.042 1.23 (0.64, 2.39) 0.54
E-ZES vs C-SES 0.81 (0.58, 1.14) 0.22 0.61 (0.39–0.95) 0.028
DAPT, dual antiplatelet therapy; HR, hazard ratio.
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Appendix 3 Patient, lesion, and procedure characteristics at baseline for patients lost to follow-up







Age (Years) 61.1+12.3 59.7+11.2 1.4 [21.0, 3.8] 0.263
Male 76.7% 76.2% 0.5% [28.1%, 9.2%] 1.000
Body mass index (kg/m2) 27.8+4.8 27.3+3.9 0.5 [20.4, 1.4] 0.232
Diabetes Mellitus 30.1% 31.1% 21.0% [210.4%, 8.4%] 0.910
Insulin dependent 6.3% 7.8% 21.5% [26.7%, 3.7%] 0.685
Hypertension 62.5% 62.2% 0.3% [29.6%, 10.2%] 1.000
Hyperlipidemia 60.2% 57.0% 3.2% [26.8%, 13.3%] 0.597
History of smoking 64.8% 57.5% 7.3% [22.7%, 17.2%] 0.166
Current smoker 37.5% 34.7% 2.8% [27.0%, 12.6%] 0.589
Premature CAD in First Degree Relative 25.0% 32.6% 27.6% [217.6%, 2.3%] 0.110
Previous myocardial infarction 17.6% 22.8% 25.2% [213.4%, 3.0%] 0.245
Previous CABG 4.0% 4.7% 20.7% [24.8%, 3.5%] 0.803
Previous PCI 11.4% 13.0% 21.6% [28.3%, 5.1%] 0.750
Previous Stroke 4.0% 4.7% 20.7% [24.8%, 3.5%] 0.803
Procedure indication
All (acute) myocardial infarctions 26.1% 28.0% 21.8% [210.9%, 7.2%] 0.726
ST-elevation 8.0% 9.3% 21.4% [27.1%, 4.4%] 0.713
Non-ST-elevation 18.2% 18.7% 20.5% [28.4%, 7.4%] 1.000
Unstable Angina 21.6% 17.6% 4.0% [24.1%, 12.1%] 0.359
Stable Angina 44.3% 45.1% 20.8% [210.9%, 9.4%] 0.917
Silent Ischemia 8.0% 9.3% 21.4% [27.1%, 4.4%] 0.713
Left ventricular ejection fraction (%) 59.3+9.8 58.2+7.9 1.0 [20.8, 2.8] 0.261
Serum Creatinine (mmol/L) 86.9+22.0 81.8+22.1 5.1 [0.6, 9.6] 0.026
Complex patients 54.5% 57.0% 22.4% [212.6%, 7.7%] 0.675
Lesion characteristics
Continued
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Vessel location (by patient)
Left anterior descendent 55.2% 62.0% 26.8% [216.9%, 3.3%] 0.203
Left circumflex 28.2% 26.0% 2.1% [27.0%, 11.2%] 0.724
Right coronary artery 31.6% 31.3% 0.4% [29.2%, 9.9%] 1.000
Left main 0.6% 2.1% 21.5% [23.8%, 0.8%] 0.375
Bypass graft 0.6% 0.0% 0.6% [20.5%, 1.7%] 0.475
In-stent restenosis 1.7% 2.1% 20.4% [23.2%, 2.4%] 1.000
Chronic total occlusion 4.0% 6.3% 22.2% [26.7%, 2.3%] 0.358
Bifurcation 19.5% 18.8% 0.8% [27.3%, 8.9%] 0.894
Moderate/severe calcification (vs none or mild) 29.3% 33.9% 24.5% [214.1%, 5.0%] 0.370
Tortuosity moderate or severe (vs mild) 25.3% 23.4% 1.8% [27.0%, 10.7%] 0.715
Presence of thrombus (vs none) 6.9% 12.0% 25.1% [211.0%, 0.9%] 0.111
Procedure characteristics
Number of vessels treated per patient 1.14+0.41 1.18+0.51 20.03 [20.13, 0.06] 0.495
Number of lesions treated per patient 1.34+0.76 1.28+0.59 0.06 [20.08, 0.20] 0.414
Number of stents per patient 1.43+0.84 1.41+0.85 0.02 [20.16, 0.19] 0.830
Total stent length/ patient (mm) 27.45+17.19 30.54+20.83 23.08 [27.03, 0.87] 0.126
Number of stents per lesion 1.08+0.37 1.13+0.62 20.05 [20.14, 0.04] 0.291
Total Lesion length per patient 22.71+14.53 24.71+16.03 22.00 [25.15, 1.16] 0.215
≥1 stent ≤2.75 mm in diameter (%) 41.4% 44.3% 22.9% [213.2%, 7.4%] 0.598
≥1 lesion overlapping stent (%) 9.8% 12.5% 22.7% [29.3%, 3.8%] 0.507
Lesions with predilatation 66.7% 66.7% 0.0% [29.7%, 9.7%] 1.000
C-SES, Cypher sirolimus-eluting stent; E-ZES, Endeavor zotarolimus-eluting stent.
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